Datasets:

protocolsyncllc
/

field-safety-notices

+{"instruction":"Audit the raw material management procedures to ensure compliance with requirements for the chemical and physical properties of materials used in implantable devices.","context":"The raw material procurement policy allows for the use of Ultra High Molecular Weight Polyethylene (UHMWPE) raw material as long as it is within the manufacturer's stated shelf life. The document does not include a specific check for industry guidance on storage duration or oxidation potential for UHMWPE. The quality control release criteria focus solely on the physical dimensions of the final implant, not the chemical integrity of the raw material used.","response":"Field Safety Notice 38740/26 issued by BfArM on 2026-09-04 reported that orthopaedic implant components were manufactured with UHMWPE raw material aged in excess of five years for Non-active implants - bone surgery. This violates Annex I, Section 10.1(d) and 10.1(h) of Regulation (EU) 2017/745, which require attention to the impact of processes on material properties and confirmation that the device meets defined chemical and physical specifications. The technical failure is the QMS's failure to incorporate industry guidance on storage duration into the raw material acceptance criteria, leading to the use of degraded material that does not meet the required chemical and physical specifications for safe implantation."}
+{"instruction":"Review the material degradation risk assessment to ensure that the impact of storage conditions on material properties is adequately addressed in the design and manufacturing process.","context":"The design verification report for the orthopaedic implants states that the UHMWPE material is stable under normal storage conditions. The document does not include any testing or analysis regarding the effects of extended storage duration on the oxidation levels of the material. The risk assessment concludes that material degradation is not a significant risk because the material is certified by the supplier, without independent verification of the material's state at the time of manufacturing.","response":"Field Safety Notice 38740/26 issued by BfArM on 2026-09-04 reported that the use of UHMWPE raw material beyond the recommended storage duration has the potential for elevated levels of oxidation for Non-active implants - bone surgery. This violates Annex I, Section 10.1(d) and 10.1(f) of Regulation (EU) 2017/745, which require particular attention to the impact of processes on material properties and the mechanical properties of the materials used. The technical failure is the lack of independent verification of material properties (specifically oxidation levels) at the point of use, relying solely on supplier certification which does not account for the specific storage history of the raw material, thereby failing to ensure the device meets the required performance and safety characteristics."}
+{"instruction":"Assess the clinical risk management process to ensure that potential harms associated with material degradation are identified and mitigated in the device design.","context":"The clinical evaluation document for the orthopaedic implants lists revision surgery, pain, and inflammation as potential harms associated with material degradation. The document states that these harms are considered 'acceptable' because they are consistent with the general risks of orthopaedic surgery. No specific mitigation measures are proposed to address the increased risk of material fragmentation or device fracture due to aged raw material.","response":"Field Safety Notice 38740/26 issued by BfArM on 2026-09-04 reported that potential harms associated with the identified material degradation include the need for revision surgery, pain, and inflammation for Non-active implants - bone surgery. This violates Annex I, Section 10.1(f) and 10.1(h) of Regulation (EU) 2017/745, which require the device to be designed and manufactured to ensure that characteristics and performance requirements are fulfilled, including mechanical properties and confirmation of chemical/physical specifications. The logical failure is the QMS's acceptance of increased clinical risks (revision surgery, inflammation) as 'acceptable' without implementing specific design or manufacturing controls to prevent the root cause (material degradation), thereby failing to minimize the risk posed by the device to the patient."}
+{"instruction":"Verify that the information provided to patients regarding implanted devices includes all necessary details for safe use and follow-up, in accordance with the implant card requirements.","context":"The patient information leaflet for the orthopaedic implants states that patients should continue to be followed per the normal protocol established by their surgeon. The document does not include specific information about the expected lifetime of the device or any necessary follow-up related to the specific material degradation risk. The implant card provided with the device contains only the device name and serial number, omitting the lot number and UDI as required for traceability.","response":"Field Safety Notice 38740/26 issued by BfArM on 2026-09-04 reported that patients treated with an impacted product are recommended to continue to be followed per the normal protocol for Non-active implants - bone surgery. This violates Article 18(1)(a) and Article 18(1)(c) of Regulation (EU) 2017/745, which require the manufacturer to provide information allowing the identification of the device (including lot number and UDI) and any information about the expected lifetime of the device and any necessary follow-up. The technical failure is the omission of critical identification data (lot number, UDI) from the implant card and the failure to provide specific follow-up information related to the known material degradation risk, thereby compromising the patient's ability to track the device and receive appropriate care."}